TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04201457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib capsule; Dabrafenib Dispersible Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib capsule; Dabrafenib Dispersible Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib capsule; Dabrafenib Dispersible Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Tablet; Powder for Oral Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Tablet; Powder for Oral Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Tablet; Powder for Oral Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Tablet; Powder for Oral Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Tablet; Powder for Oral Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Tablet; Powder for Oral Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Tablet
Study: NCT04519619

Intervention type: DRUG
Intervention: Aflibercept (Eylea, BAY86-5321)
Description: Administration by intravitreal injection
Study: NCT01224613

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intanza
Description: 0.1 mL of Intanza intradermally at visit # 1
Study: NCT01303718

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioFit® System
Description: Vagal nerve stimulation with the CardioFit® system

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Usual care for LV dysfunction and heart failure (no CardioFit System implant)
Study: NCT01183520

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fish oil provided by salmon
Description: Eating 3 different amounts of provided salmon twice a week for four weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fish oil provided by salmon
Description: Eating 3 different amounts of provided salmon twice a week for four weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fish oil provided by salmon
Description: Eating 3 different amounts of provided salmon twice a week for four weeks
Study: NCT00201422

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omeprazole, Amoxicillin, Clarithromycin
Description: Omeprazole20 mg,Clarithromycin500 mg b.i.d.,Day 1-14 plus Amoxicillin 500 mg q.i.d.,Day 1-14 plus
Study: NCT04838054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stabilized chlorine dioxide oral rinse
Description: Patients received stabilized chlorine dioxide rinse associated with periodontal basic therapy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients received a rinse containing no active ingredients and periodontal basic therapy.
Study: NCT04150146

Intervention type: DRUG
Group type: OTHER
Intervention: Rebamipide SR 150mg after high-fat meal
Description: Test Drug

Intervention type: DRUG
Group type: OTHER
Intervention: Rebamipide SR 150mg after high-fat meal
Description: Test Drug

Intervention type: DRUG
Group type: OTHER
Intervention: Rebamipide SR 150mg under fasting condition
Description: Reference Drug

Intervention type: DRUG
Group type: OTHER
Intervention: Rebamipide SR 150mg under fasting condition
Description: Reference Drug
Study: NCT04494542

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sustained Low Efficiency Dialysis (SLED)
Description: sustained low efficiency dialysis (SLED)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Renal Replacement Therapy
Description: Continuous Renal Replacement Therapy
Study: NCT02193737

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early oral fluid recovery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed oral fluid recovery.
Study: NCT02957747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHE
Description: SHE is a computer-delivered intervention (Safety and Health Experiences Program; SHE) that will provide a screening and brief behavior intervention for women Veterans with any lifetime ST. More specifically, the intervention, SHE, will address interrelated health concerns for women Veterans with ST (i.e. alcohol misuse, IPV, and PTSD). SHE will provide individualized assessment, feedback, and referrals for women Veterans with any lifetime ST. SHE will take place within a primary care setting.
Study: NCT01228136

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: 10mg/Kg, IV (in the vein), first dose 30 minutes before surgery, second dose 8 hours after first dose, third dose 8 hours after second dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline solution
Description: normal saline solution in the same volume calculated as treatment (tranexamic acid 250mg/mL, 10mg/Kg), IV (in the vein) first dose 30 minutes before surgery, second dose 8 hours after first dose, third dose 8 hours after second dose
Study: NCT04660851

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coached
Description: 10-weeks of diet coaching weekly by telephone to improve dietary protein intake
Study: NCT03590626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: 0.75 mg weekly for 4 weeks followed by 1.5 mg weekly for 20 weeks
Study: NCT04098419

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Science for Life
Description: The implementation for both school years will follow the same procedures with different cohorts. Sixteen adolescents will be recruited through existing after-school programs at each location (32 total each year). College interns will facilitate food literacy lessons after school once per week with high school-aged adolescents. Beginning in January, adolescents will participate in training led by project staff and college interns to become competent cross-age teachers for garden-enhanced nutrition curricula. This training will consist of instruction in utilization of inquiry-based teaching practices and will be followed by adolescents practicing facilitating the curricula in teaching pairs. Up to 32 younger youth participants at each location (up to 64 total each year) will be recruited from local elementary schools while adolescents complete the cross-age teaching training. With mentorship from college interns, adolescents will facilitate curricula in pairs with younger youth.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Science for Life
Description: The implementation for both school years will follow the same procedures with different cohorts. Sixteen adolescents will be recruited through existing after-school programs at each location (32 total each year). College interns will facilitate food literacy lessons after school once per week with high school-aged adolescents. Beginning in January, adolescents will participate in training led by project staff and college interns to become competent cross-age teachers for garden-enhanced nutrition curricula. This training will consist of instruction in utilization of inquiry-based teaching practices and will be followed by adolescents practicing facilitating the curricula in teaching pairs. Up to 32 younger youth participants at each location (up to 64 total each year) will be recruited from local elementary schools while adolescents complete the cross-age teaching training. With mentorship from college interns, adolescents will facilitate curricula in pairs with younger youth.
Study: NCT03294044

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICT programs
Description: ICT programs that include health information learning by disease and self-management based on Smart Management Strategy for Health (SMASH).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A book about chronic disease
Description: A Take-home book about chronic disease are provided for self-education
Study: NCT01242839

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CACICOL20
Description: CACICOL20 is a solution of dextran \& poly(carboxymethylglucose sulphate)in physiological salt serum. CACICOL20 is presented in 0.33 mL strip. One drop is instilled at each application to impregnate cornea.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CACICOL20
Description: CACICOL20 is a solution of dextran \& poly(carboxymethylglucose sulphate)in physiological salt serum. CACICOL20 is presented in 0.33 mL strip. One drop is instilled at each application to impregnate cornea.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It is the placebo of CACICOL20, containing dextran in physiological serum salt. It is presented, like CACICOL20, in a 0.33 mL strip. One drop is delivered at each application.
Study: NCT00321074

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TACROLIMUS
Description: Immunosuppression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACROLIMUS
Description: Immunosuppression
Study: NCT02184091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Study: NCT03515135

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive Executive Function Training
Description: Training the executive funtions of preshcool ADHD children through tasks and games repeatly but with fun. Giving the parents strategies to help the prechool ADHD childred coping the symptoms and develop EF in the reallife.
Study: NCT02966028

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered 3 times weekly by intravenous infusion through the dialysis machine in conjunction with the patient's dialysis sessions.
Study: NCT03764566

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: The intervention will include the implication of related questionnaires, followed by a lab experiment for social belonging with multiple modalities. Participants will be shown pictures of different faces and asked to judge their feelings towards them. Further, a VR task will include finding the way through a virtual maze with the help of two virtual characters.
Study: NCT01224613

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intanza
Description: 0.1 mL of Intanza intradermally at visit #1
Study: NCT00569387

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HyperAcute(R)-Pancreatic Cancer Vaccine
Description: 100 million vaccine cells will be injected intradermally for up to 14 vaccinations over approximately 8 months
Study: NCT02629224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8825
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8825
Description: Oral
Study: NCT02574611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline (Placebo)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Resolution Colonic Manometry

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Resolution Colonic Manometry

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Resolution Colonic Manometry

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: High Resolution Colonic Manometry
Study: NCT03872063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: The intervention by myofascial induction will consist of the application of two techniques: global technique of myofascial induction of the pectoralis major muscle (once the tissue is placed in tension, the direction of fascia release in that region should be followed and as a result of the release, the caudal hand can move to the pelvis in any direction, to the right or to the left) and telescopic technique for the upper extremity of the subject's dominant arm (gently tractioning the upper limb of the subject, making a slight external rotation, so slow and progressive). The subjects will then perform the eccentric exercises, which will also be done by control group subjects

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The intervention by eccentric exercises will consist of two exercises using an elastic band. In the supine position, with the elastic band on the contralateral side attached to a fixed body perpendicular to the subject's hand performing a slow and constant movement of external rotation against resistance in an approximately 45 degree arc; holding for 5 seconds and relaxing slowly (perform 3 sets of 12 repetitions). The second exercise, with the elbow in 90 degrees of flexion and a shoulder abduction also of 90 degrees, with the elastic band in front of the subject, executing a movement against resistance performing an external rotation.
Study: NCT02043041

Intervention type: OTHER
Intervention: Number of DBS Spots
Description: The number of DBS spots on the card constitutes the experimental condition.

Intervention type: OTHER
Intervention: Number of DBS Spots
Description: The number of DBS spots on the card constitutes the experimental condition.

Intervention type: OTHER
Intervention: Number of DBS Spots
Description: The number of DBS spots on the card constitutes the experimental condition.
Study: NCT03764566

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: The intervention will include the implication of related questionnaires, followed by a lab experiment for social belonging with multiple modalities. Participants will be shown pictures of different faces and asked to judge their feelings towards them. Further, a VR task will include finding the way through a virtual maze with the help of two virtual characters.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: The intervention will include the implication of related questionnaires, followed by a lab experiment for social belonging with multiple modalities. Participants will be shown pictures of different faces and asked to judge their feelings towards them. Further, a VR task will include finding the way through a virtual maze with the help of two virtual characters.
Study: NCT02550288

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Ezetimibe 10 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Ezetimibe 10 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Atorvastatin 10 mg capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Atorvastatin 10 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Atorvastatin 10 mg capsule

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet control/Daily Exercise
Description: Diet and Daily exercise program as per Japan Atherosclerosis Society Guideline 2012 (JAS2012)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet control/Daily Exercise
Description: Diet and Daily exercise program as per Japan Atherosclerosis Society Guideline 2012 (JAS2012)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet control/Daily Exercise
Description: Diet and Daily exercise program as per Japan Atherosclerosis Society Guideline 2012 (JAS2012)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet control/Daily Exercise
Description: Diet and Daily exercise program as per Japan Atherosclerosis Society Guideline 2012 (JAS2012)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet control/Daily Exercise
Description: Diet and Daily exercise program as per Japan Atherosclerosis Society Guideline 2012 (JAS2012)
Study: NCT02384473

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Real-Time CEUS
Description: Undergo real-time CEUS

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SWE
Description: Undergo SWE

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Definity Suspension for Injection
Description: Participant will receive contrast agent by intravenous administration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips Shear Wave Elastography
Description: Type of equipment used for SWE
Study: NCT04548934

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personal protective equipment (PPE)
Description: Wearing of PPE (FFP3 mask, gloves, eye protection, long-sleeved gown)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No Personal protective equipment (PPE)
Description: Standard CPR without wearing PPE
Study: NCT00606034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U-500 Insulin delivered by Omnipod (disposable insulin pump)
Description: U-500 insulin (concentrated insulin) will be infused continuously subcutaneously using a disposable insulin pump called an Omnipod; the insulin infusion dosage will be individualized to each subject's needs
Study: NCT01243372

Intervention type: GENETIC
Intervention: mutation analysis

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Study: NCT03037359

Intervention type: BIOLOGICAL
Intervention: Bivigam
Description: Human immune globulin

Intervention type: BIOLOGICAL
Intervention: Other
Description: Human immune globulin
Study: NCT03116802

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stamaril (live attenuated yellow fever vaccine)
Description: They will receive a single dose of 0.5ml of Stamaril (live attenuated yellow fever vaccine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stamaril (live attenuated yellow fever vaccine)
Description: They will receive a single dose of 0.5ml of Stamaril (live attenuated yellow fever vaccine)
Study: NCT02078180

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: generic bupropion
Description: We are comparing different formulations of bupropion that release this drug at different rates. The abbreviation IR75 means immediate release and the number is the dose in mg. The other abbreviations represent SR for sustained-release and XL for extended release, which release the drug slower than the IR formulation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: generic bupropion
Description: We are comparing different formulations of bupropion that release this drug at different rates. The abbreviation IR75 means immediate release and the number is the dose in mg. The other abbreviations represent SR for sustained-release and XL for extended release, which release the drug slower than the IR formulation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: generic bupropion
Description: We are comparing different formulations of bupropion that release this drug at different rates. The abbreviation IR75 means immediate release and the number is the dose in mg. The other abbreviations represent SR for sustained-release and XL for extended release, which release the drug slower than the IR formulation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: generic bupropion
Description: We are comparing different formulations of bupropion that release this drug at different rates. The abbreviation IR75 means immediate release and the number is the dose in mg. The other abbreviations represent SR for sustained-release and XL for extended release, which release the drug slower than the IR formulation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: generic bupropion
Description: We are comparing different formulations of bupropion that release this drug at different rates. The abbreviation IR75 means immediate release and the number is the dose in mg. The other abbreviations represent SR for sustained-release and XL for extended release, which release the drug slower than the IR formulation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: generic bupropion
Description: We are comparing different formulations of bupropion that release this drug at different rates. The abbreviation IR75 means immediate release and the number is the dose in mg. The other abbreviations represent SR for sustained-release and XL for extended release, which release the drug slower than the IR formulation.
Study: NCT02995161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987521
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z43-106)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF control
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
Study: NCT03122678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study: NCT03525301

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: 3000 cGy in 10 daily fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: short course treatment
Description: 1800 cGy in 4 fractions administered twice a day
Study: NCT00332020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY59-7939)
Description: 10 mg rivaroxaban (tablet) once daily administered for 35 +/- 4 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: 40 mg enoxaparin syringe administered for 12 +/- 2 days
Study: NCT04571424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB133 (Dapirolizumab pegol)
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB133 (Dapirolizumab pegol)
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm
Study: NCT02503670

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychoeducational modules to prevent/reduce depression
Description: Psychoeducational learning modules and tools. Men will choose modules based on interest and need.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Continue with standard care.